Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

ThromboGenics N.V.. (3/15/18). "Press Release: ThromboGenics Business Update – FY 2017". Leuven.

Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Group Oxurion (Group)
  Organisation 2 Oncurious N.V.
  Group Oxurion (Group)
Products Product Jetrea®
  Product 2 THR-317 (ThromboGenics)
Index term Index term Novartis–ThromboGenics: ocriplasmin, 201203– 201709 commercialisation rights for Jetrea outside US to Alcon €75m upfront + €300m ms TERMINATED 9/17
Persons Person De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)
  Person 2 Vangeersdaele, Vinciane (ThromboGenics 201711– CCO before Novartis Ophthalmics)
     


   
Record changed: 2018-09-25

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Oxurion (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top